Vectus Biosystems Limited

Equities

VBS

AU000000VBS9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 10:38:56 28/05/2024 am IST			5-day change	1st Jan Change
0.13 ^AUD	-.--%		-.--%	-56.67%

23/05	Vectus Biosystems Appoints CTO	MT
20/05	Vectus Biosystems CEO Passes Away	MT

Vectus Biosystems Limited Announces the Change of its Registered Office and Principal Place of Business Address

December 04, 2023 at 05:36 am IST

Vectus Biosystems Limited announced that its Registered Office and Principal Place of Business has changed from Primrose Avenue, Rosebery to its new Registered Office and Principal Place of Business located at: Level 3, 11 Julius Avenue, North Ryde, NSW 2113 Australia.

Latest news about Vectus Biosystems Limited

Vectus Biosystems Appoints CTO	23/05	MT
Vectus Biosystems CEO Passes Away	20/05	MT
Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02	CI
Vectus Biosystems Limited Announces the Change of its Registered Office and Principal Place of Business Address	04/12	CI
Vectus Biosystems Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Vectus Biosystems Enrolls Patients, Begins Trials for Hypertension, Low Cardiovascular Risk Drug	15/23/15	MT
Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
Vectus Biosystems to Raise $2.3 Million From Share Placement	23/22/23	MT
Vectus Biosystems Halts Securities Trading Pending Fundraising Announcement	21/22/21	MT
Vectus Biosystems Limited Auditor Raises 'Going Concern' Doubt	29/22/29	CI
Vectus Biosystems Completes Phase Ia for Hypertension and Cardiovascular Drug	14/22/14	MT
Vectus Biosystems Limited Announces Completion of Phase Ia for VB0004	14/22/14	CI
Vectus Biosystems Limited Reports Earnings Results for the Full Year Ended June 30, 2022	31/22/31	CI
Vectus Biosystems Limited Announces Completion of Second M.A.D. Study for Vb0004	08/22/08	CI
Vectus Biosystems Limited Announces Completion of Final Single Ascending Dose Study and First Multiple Ascending Dose Study for VB0004	25/22/25	CI
Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2021	25/22/25	CI
Vectus Biosystems Limited Announces Fourth of the Five Planned Cohorts in the Single Ascending Dose Segment of Its First-In-Human Tria	21/22/21	CI
Vectus Biosystems Limited Announces Third S.A.D. Group Reviewed by Trial Safety Review Committee	29/21/29	CI
Vectus Biosystems : Finishes Second SAD Segment of First-in-Human Hypertension Drug Trial	07/21/07	MT
Vectus Biosystems Limited Reports Earnings Results for the Full Year Ended June 30, 2021	31/21/31	CI
Vectus Biosystems : Completes Phase One Human Trial for Cardiovascular Disease	23/21/23	MT
Vectus Biosystems Limited Announces Successful Completion of First Group in Phase I Human Trial	23/21/23	CI
Vectus Biosystems : HREC Approves Vectus Biosystems' Phase One Human Trial for Hypertension Drug in Australia; Shares Surge 30%	17/21/17	MT
Approval Receives Approval from the Human Research Ethics Committee for Phase I Trial in Australia	17/21/17	CI
Vectus Biosystems Limited Reports Earnings Results for the Half Year Ended December 31, 2020	26/21/26	CI

Chart Vectus Biosystems Limited

Duration

Period

More charts

Company Profile

Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VECTUS BIOSYSTEMS LIMITED	-56.67%	4.59M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research